EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Histology independent drug development – Is this the future for cancer drugs?

Lucinda Billingham, Lynn Brown, Theodor Framke, Alastair Greystoke, Eivind Hovig, Siddhartha Mathur, Philippe Page, Elias Pean, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander und 1 weitere

Cancer Treatment Reviews · 2024

DOI: 10.1016/j.ctrv.2023.102674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024. Verfasst von Lucinda Billingham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Electronic address: L.J.Billingham@b…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansDrug DevelopmentMedical OncologyBiomarkers, TumorAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

BiomarkerCancer trialData sharingHistology independentTumour agnostic

Substanzen

Antineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Electronic address: L.J.Billingham@bham.ac.uk.
  • Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: lynn.may.brown@merck.com.
  • European Medicines Agency, Amsterdam, The Netherlands. Institute for Biostatistics, Hannover Medical School, Hannover, Germany. Electronic address: theodor.framke@ema.europa.eu.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: Alastair.greystoke@newcastle.ac.uk.
  • Centre for Bioinformatics, University of Oslo, P.O. Box 1080 Blindern, 0316 OSLO, Norway; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway. Ele…
  • Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: siddhartha.mathur@merck.com.

Förderung

  • Cancer Research UK

Zitieren

APA

Billingham, L., Brown, L., Framke, T., Greystoke, A., Hovig, E., Mathur, S., Page, P., Pean, E., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Vonk, R., Wissink, S., Zander, H., & Plummer, R. (2024). Histology independent drug development – Is this the future for cancer drugs?. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102674

Vancouver

Billingham L, Brown L, Framke T, Greystoke A, Hovig E, Mathur S, et al. Histology independent drug development – Is this the future for cancer drugs?. Cancer Treatment Reviews. 2024. doi:10.1016/j.ctrv.2023.102674

BibTeX
@article{Billingham2024,
  author = {Billingham, Lucinda and Brown, Lynn and Framke, Theodor and Greystoke, Alastair and Hovig, Eivind and Mathur, Siddhartha and Page, Philippe and Pean, Elias and Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar and Vonk, Richardus and Wissink, Sacha and Zander, Hilke and Plummer, Ruth},
  title = {Histology independent drug development – Is this the future for cancer drugs?},
  journal = {Cancer Treatment Reviews},
  year = {2024},
  doi = {10.1016/j.ctrv.2023.102674}
}
Kostenlos starten →